North America Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays, Chemiluminescence Immunoassays, Radioimmunoassays, and Others), By Clinical Indication, and End User

List of Tables

The North America immunodiagnostics market is expected to grow from US$ 10,463.48 million in 2023 to US$ 17,399.10 million by 2030. It is estimated to grow at a CAGR of 7.5% from 2023 to 2030.

Growing Use of Point-of-Care Immunodiagnostics Drive North America Industrial Robotics Market

Point-of-care testing (POCT) has become critical to patient-centric healthcare due to the need for rapid diagnostic results to determine accurate and faster treatments. A shift from centralized point-of-care testing to decentralized testing has resulted in easy access to these diagnostics. Immunoassay testing helps monitor chronic conditions and detect pathogens, such as bacteria and viruses. Advanced point-of-care devices enable rapid screening of up to three components from a single sample. Also, the point-of-care diagnostics (POCD) inclined toward mobile healthcare (mH) smart devices could revolutionize personalized healthcare monitoring and management, paving the way for next-generation POCTs. The management of infectious diseases can be significantly improved by POCTs, particularly in developing countries where access to timely medical care is challenging and healthcare infrastructure is outdated and sparse. Additionally, the technologically developed diagnostic kits leading to fewer manual errors propel the immunodiagnostics market. Several market players are developing innovative immunodiagnostics products. For instance, Thermo Fisher Scientific has developed immunodiagnostics products such as enzyme-linked immunoassay (ELISA) reagents and buffers, antibodies and detection probes, linking mechanisms, blocking buffers and detergents, detection substrates, and capture surfaces, as well as services such as bioconjugation and detection. Further, in September 2020, Roche launched the SARS-CoV-2 Rapid Antigen Test, which is used in POC settings to help healthcare professionals identify the infection within 15 minutes in people suspected of carrying the virus.

In April 2021, DiaSorin introduced the LIAISON IQ, a new immunodiagnostics Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics for countries accepting the CE Mark. Using a fingerstick of human capillary blood, this test for the LIAISON IQ identifies specific IgG antibodies against SARS-CoV-2 Spike Protein in 10 minutes.

In April 2021, Chembio Diagnostics, Inc. launched an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test for use in traditional and decentralized testing settings. The rapid immunoassay test requires no instrumentation and produces results in 15 minutes.

WHO applauded the test kit developers for efforts taken to innovate and respond to the masses' requirements during the COVID-19 crisis. According to the American Society for Clinical Pathology, in March 2020, the Cepheid Xpert Xpress SARS-CoV-2 test became the first POC COVID-19 detection assay to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).

Likewise, the use of immunodiagnostics in cancer treatment is increasing. In oncology, an immunodiagnostics test can confirm the presence of a solid tumor by detecting known tumor-associated antigens or antibodies. These advantages and indications are driving the immunodiagnostics market.

North America Immunodiagnostics Market Overview

The prevalence of cancer is increasing in the country at an alarming rate, leading to the rising demand for cancer diagnoses. According to the American Cancer Society's (ASC) cancer facts & figures estimates for 2023, nearly 1.9 million new cancer cases were registered in the US. It is further projected that in 2023, the country will register 609,360 deaths from cancer, which is ~1,670 deaths a day. However, the increased diagnostics have reduced the number of cancer-linked deaths. As per the ASC, in the past 28 years, the death rate from cancer in men and women has fallen 32% from its peak in 1991 to 2019. The fall in death rates was found to be because of early and advanced cancer diagnoses. The awareness of the advancements in diagnostic technology has grown among people. Therefore, it has resulted in the significant growth of the immunoassay market in the US. Similarly, diabetes is prevailing at a high rate in the geriatric population in the US. Many companies are providing immunoassay kits for diabetes. For instance, Bio-Rad Laboratories, Inc. offers Bio-Plex Pro human diabetes immunoassays, which are reliable and convenient for studying human diabetes and obesity markers. They help in managing and treating diabetes in diabetic patients. The market is expected to witness significant growth due to the rising prevalence of diabetes among US citizens. According to the data published by the Centers for Disease Control and Prevention (CDC) in the 2023 National Diabetes Statistics Report, 37.3 million people have diabetes in the US, which accounts for 11.3% of the total US population. Also, the reports state that 96 million people aged 18 years or above are prediabetic, accounting for 38% of the US population. Thus, considering the prevalence of diabetes in the country, an increased demand for immunodiagnostics is anticipated, leading to market growth. There has been unprecedented growth in innovative and improved medical technologies in recent years. As a result, there have been developments in advanced diagnostics and the overall healthcare industry. Moreover, the US houses various companies developing cutting-edge products for point-of-care diagnosis, paving the way for the growth of the immunodiagnostics market. In April 2020, Bio-Rad Laboratories launched a blood-based immunoassay kit to identify antibodies to the SARS-CoV-2.

North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

North America Immunodiagnostics Market Segmentation

The North America immunodiagnostics market is segmented into product, clinical indication, end user, and country.

Based on product, the North America immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered the largest share in the North America immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the North America immunodiagnostics market is segmented into infectious diseases, hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered the largest share in the North America immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the North America immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered the largest share in the North America immunodiagnostics market.

Based on country, the North America immunodiagnostics market is segmented into the US, Canada, Mexico. In 2023, the US registered the largest share in the North America immunodiagnostics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America immunodiagnostics market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America immunodiagnostics market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America immunodiagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the immunodiagnostics market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Product Code: BMIRE00029028

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Immunodiagnostics Market - by Product
- 1.3.2 North America Immunodiagnostics Market - by Clinical Indication
- 1.3.3 North America Immunodiagnostics Market - by End User
- 1.3.4 North America Immunodiagnostics Market - by Country

2. North America Immunodiagnostics Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Immunodiagnostics Market - Market Landscape

4.1 Overview
4.2 North America PEST Analysis
4.3 Expert's Opinion

5. North America Immunodiagnostics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Infectious Diseases
- 5.1.2 Growing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
- 5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
- 5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
5.4 Future Trends
- 5.4.1 Technological Advancements in Immunodiagnostics
5.5 Impact Analysis

6. Immunodiagnostics Market - North America Analysis

6.1 North America Immunodiagnostics Market Revenue Forecast and Analysis

7. North America Immunodiagnostics Market Analysis - by Product

7.1 Overview
7.2 North America Immunodiagnostics Market, By Product, 2022 & 2030 (%)
7.3 Enzyme-linked Immunosorbent Assays (ELISA)
- 7.3.1 Overview
- 7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
- 7.4.1 Overview
- 7.4.2 Chemiluminescence Immunoassays (CLIA): North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.3 Vitamin D Assay
  - 7.4.3.1 Overview
  - 7.4.3.2 Vitamin D Assay: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.4 HIV Detection
  - 7.4.4.1 Overview
  - 7.4.4.2 HIV Detection: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.5 HIV Ag/Ab Combo assay
  - 7.4.5.1 Overview
  - 7.4.5.2 HIV Ag/Ab Combo Assay: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.6 Other Tests
  - 7.4.6.1 Overview
  - 7.4.6.2 Other Tests: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Radioimmunoassays (RIA)
- 7.5.1 Overview
- 7.5.2 Radioimmunoassays (RIA): North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

8. North America Immunodiagnostics Market Analysis - Clinical Indication

8.1 Overview
8.2 North America Immunodiagnostics Market Share by Clinical Indication - 2022 & 2030 (%)
8.3 Infectious Diseases:
- 8.3.1 Overview
- 8.3.2 Infectious Diseases: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 COVID-19
    - 8.3.2.1.1 Overview
    - 8.3.2.1.2 COVID-19: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Tuberculosis
    - 8.3.2.2.1 Overview
    - 8.3.2.2.2 Tuberculosis: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.3 Lyme
    - 8.3.2.3.1 Overview
    - 8.3.2.3.2 Lyme: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.4 Infection Management
    - 8.3.2.4.1 Overview
    - 8.3.2.4.2 Infection Management: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.5 Zika
    - 8.3.2.5.1 Overview
    - 8.3.2.5.2 Zika: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.6 Treponema
    - 8.3.2.6.1 Overview
    - 8.3.2.6.2 Treponema: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.7 TORCH
    - 8.3.2.7.1 Overview
    - 8.3.2.7.2 TORCH: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.8 Measles and Mumps
    - 8.3.2.8.1 Overview
    - 8.3.2.8.2 Measles and Mumps: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.9 VZV
    - 8.3.2.9.1 Overview
    - 8.3.2.9.2 VZV: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.10 EBV
    - 8.3.2.10.1 Overview
    - 8.3.2.10.2 EBV: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.4 Hepatitis+HIV:
- 8.4.1 Overview
- 8.4.2 Hepatitis+HIV: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Gastrointestinal
- 8.5.1 Overview
- 8.5.2 Gastrointestinal: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.6 Metabolic Disorders
- 8.6.1 Overview
- 8.6.2 Metabolics: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7 Endocrinology
- 8.7.1 Overview
- 8.7.2 Endocrinology: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.3 Hypertension
  - 8.7.3.1 Overview
  - 8.7.3.2 Hypertension: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.4 Growth
  - 8.7.4.1 Overview
  - 8.7.4.2 Growth: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.5 Diabetes
  - 8.7.5.1 Overview
  - 8.7.5.2 Diabetes: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.6 Thyroid
  - 8.7.6.1 Overview
  - 8.7.6.2 Thyroid: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.7 Reproductive Endocrinology
  - 8.7.7.1 Overview
  - 8.7.7.2 Reproductive Endocrinology: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

9. North America Immunodiagnostics Market Analysis - End User

9.1 Overview
9.2 North America Immunodiagnostics Market Share by End User - 2022 & 2030 (%)
9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 Hospitals: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Clinics
- 9.4.1 Overview
- 9.4.2 Clinics: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Diagnostic Laboratories
- 9.5.1 Overview
- 9.5.2 Diagnostic Laboratories: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.6 Academic and Research Institutes
- 9.6.1 Overview
- 9.6.2 Academic and Research Institutes: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.7 Others
- 9.7.1 Overview
- 9.7.2 Others: North America Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

10. North America Immunodiagnostics Market - Revenue and Forecast to 2030 - Country Analysis

10.1 Overview

11. North America Immunodiagnostics Market -Industry Landscape

11.1 Overview
11.2 Inorganic Growth Strategies
- 11.2.1 Overview
11.3 Organic Growth Strategies
- 11.3.1 Overview

12. Company Profiles

12.1 Abbott Laboratories
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 DiaSorin SpA
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Danaher Corp
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 PerkinElmer Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 bioMerieux SA
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Svar Life Science AB
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Siemens Healthcare GmbH
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms